Physician profile
Tomy Starck
NPI 1972641751
$5,888.89
in general payments reported to CMS, 2019-2025
21 companies · $540 in 2025
The $540 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,615 · 2020: $280 · 2021: $770 · 2022: $623 · 2023: $433 · 2024: $628 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,611.21 | 2019-2022 | |
| Alcon Vision LLC | $1,301.21 | 2019-2025 | Clareon, Argos, Total30 |
| Bausch & Lomb Americas INC. | $506.57 | 2022-2025 | Miebo, Prolensa, Vyzulta |
| Novartis Pharmaceuticals Corporation | $180.08 | 2019-2022 | |
| Sight Sciences, INC. | $178.83 | 2022-2025 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $160.20 | 2019-2021 | |
| Oyster Point Pharma, INC. | $145.39 | 2022-2025 | Tyrvaya, Ryzumvi |
| Carl Zeiss Meditec USA, INC. | $137.13 | 2021 | |
| Allergan, INC. | $121.06 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $119.67 | 2019-2021 | |
| Harrow Eye, LLC | $99.41 | 2024 | Vevye |
| Mallinckrodt Hospital Products INC. | $54.15 | 2024-2025 | Acthar |
| Tarsus Pharmaceuticals, INC. | $50.88 | 2024 | Xdemvy |
| Abbvie INC. | $50.36 | 2023-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $48.15 | 2020-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $31.05 | 2024-2025 | Oxervate |
| Tearlab Corp | $27.92 | 2023 | Tearlab Osmolarity System |
| Shire North American Group INC | $20.71 | 2019 | |
| Amgen INC. | $16.54 | 2024 | Tepezza |
| Aerie Pharmaceuticals, INC. | $15.50 | 2019 | |
| Rxsight INC | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomy Starck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.